Ascendiant Capital Initiates Coverage On RenovoRx with Buy Rating, Announces Price Target of $8
Portfolio Pulse from Benzinga Newsdesk
Ascendiant Capital has initiated coverage on RenovoRx (NASDAQ:RNXT) with a Buy rating and set a price target of $8.
June 17, 2024 | 11:00 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Ascendiant Capital has initiated coverage on RenovoRx with a Buy rating and set a price target of $8, indicating a positive outlook for the stock.
The initiation of coverage with a Buy rating and a price target of $8 by Ascendiant Capital is likely to boost investor confidence in RenovoRx, potentially driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100